Other Routine +

Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners Clinical Execution Continues Amidst Severe Capital Erosion and Liquidity Concerns

By The Northwire Desk — AI Analysis Apr 30, 2026 · 07:00 ARCH · 0.435 Arch Biopartners Inc.

Executive Summary

Clinical Trial Progress: Royal Columbian Hospital (RCH) has commenced patient recruitment for the Phase II LSALT peptide trial targeting cardiac surgery-associated acute kidney injury (CS-AKI).
Site Expansion: RCH is the ninth global site and fourth Canadian site to begin recruiting. Active sites include Toronto General, St. Michael’s, and University of Calgary.
Future Expansion: Feasibility discussions are ongoing for three US sites and one additional Ontario site.
Trial Parameters: International, multi-center, randomized, double-blind, placebo-controlled study targeting 240 patients using KDIGO criteria within seven days post-surgery.
Corporate Governance: Board granted 150,000 stock options to a new director at $1.05 per share, exercisable for 10 years.
Pipeline Context: LSALT peptide is in Phase II; Cilastatin (Phase II toxin-induced AKI) and CKD platform are also mentioned as active development areas.

Material Impact

Execution vs. Expectation: The news confirms the execution of a milestone previously announced on March 24, 2026 (Clinical Trial Agreement signed with Fraser Health Authority). This is an expected operational step rather than a surprise catalyst.
Valuation Impact: Given the stock's significant decline from $1.70 to $0.44 over the past year, this news does not materially alter the risk/reward profile. The market has already priced in the dilution and cash burn risks associated with Phase II trials.
Financial Context: The company recently closed a private placement on April 2, 2026, raising only $600,000 CAD at $0.60 per share. This capital raise is minimal for a multi-site Phase II trial involving 240 patients, suggesting reliance on grants or further dilution in the near term.
Risk Profile: While clinical progress is positive, the lack of top-line data and the small financing size indicate continued execution risk without immediate financial security.

ARCH · Price

Company Overview

Company Focus: Arch Biopartners develops therapies for acute kidney injury (AKI) and chronic kidney disease (CKD).
Flagship Asset: LSALT peptide, a first-in-class DPEP1 inhibitor targeting inflammation-mediated organ injury. Currently in Phase II for CS-AKI.
Secondary Assets: Cilastatin (Phase II for toxin-induced AKI) and a CKD platform including an IL-32 targeted drug candidate (IND filing expected within 12-18 months).
Development Stage: Clinical Phase II. Preclinical/Early Clinical for CKD platform.
Geographic Footprint: Primarily Canada with plans to expand into the US.

More from Arch Biopartners Inc.